erlotinib hydrochloride has been researched along with nad in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (nad) | Trials (nad) | Recent Studies (post-2010) (nad) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 30,121 | 88 | 5,663 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baek, M; Cheon, SH; Cho, S; Choi, Y; Chung, SJ; Jeong, YS; Jung, KY; Kim, D; Kim, DG; Kim, HS; Koh, CH; Koo, JS; Lee, BJ; Lee, HH; Lee, JY; Lee, KY; Lee, SJ; Lim, HJ; Oh, YK; Park, SJ; Shin, KS; Yoon, HJ | 1 |
1 other study(ies) available for erlotinib hydrochloride and nad
| Article | Year |
|---|---|
Crystal structures of human NSDHL and development of its novel inhibitor with the potential to suppress EGFR activity.
Topics: 3-Hydroxysteroid Dehydrogenases; Binding Sites; Cell Line, Tumor; Cell Survival; Cholesterol; Crystallography, X-Ray; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kinetics; Molecular Docking Simulation; Mutagenesis, Site-Directed; NAD; Protein Structure, Tertiary; Recombinant Proteins; Signal Transduction | 2021 |